A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD
Recruiting
Observational Study
Neovascular (Wet) Age-related Macular Degeneration
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 50 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 83 (estimated)
- Sponsor
- Skyline Therapeutics · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a Prospective, Non-interventional, Multicenter, Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients with Neovascular (Wet) Age-related Macular Degeneration (nAMD). All subject who completed the parent clinical study (NCT06213038 and NCT05986864) will undergo safety and efficacy assessments up to 5 years post study drug injection.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Subjects who only meet all of the following criteria are eligible for this study:
* nAMD subjects who have been enrolled in the SKG0106-related study and received SKG0106 injection;
* Subjects who voluntarily sign an informed consent form (ICF) and comply with the protocol to c…
Contacts